Free Trial
NYSE:NSPR

InspireMD 11/6/2023 Earnings Report

InspireMD logo
$2.70 +0.10 (+3.85%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$2.72 +0.02 (+0.70%)
As of 05/2/2025 04:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InspireMD EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.02
One Year Ago EPS
-$0.58

InspireMD Revenue Results

Actual Revenue
$1.56 million
Expected Revenue
$1.50 million
Beat/Miss
Beat by +$60.00 thousand
YoY Revenue Growth
N/A

InspireMD Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Conference Call Audio

Earnings Conference Call
InspireMD
00:00 / 00:00

InspireMD Earnings Headlines

Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
InspireMD files $200M mixed securities shelf
See More InspireMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InspireMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InspireMD and other key companies, straight to your email.

About InspireMD

InspireMD (NYSE:NSPR), a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

View InspireMD Profile

More Earnings Resources from MarketBeat